MET and malignant biphasic mesothelioma: In order to explore the potential therapeutic value of the expression of MET and AXL in mesothelioma, we evaluated the expression level of these protein in four human mesothelioma cell lines, representative of different mesothelioma subtypes: H2452, H2052, H28 and MSTO, epithelial, sarcomatoid and biphasic mesothelioma, respectively.